​

Sagimet Biosciences (SGMT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SGMT Stock Forecast

Sagimet Biosciences (SGMT) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $20.00, with a high of $29.00 and a low of $7.00. This represents a 119.30% increase from the last price of $9.12.

$5 $10 $15 $20 $25 $30 High: $29 Avg: $20 Low: $7 Last Closed Price: $9.12

SGMT Stock Rating

Sagimet Biosciences stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (88.89%), 1 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 8 Strong Sell Sell Hold Buy Strong Buy

SGMT Price Target Upside V Benchmarks

TypeNameUpside
StockSagimet Biosciences119.30%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-45
Avg Price Target-$20.00$17.60
Last Closing Price$9.12$9.12$9.12
Upside/Downside-119.30%92.98%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2629-1-12
Oct, 2629-1-12
Sep, 26181--10
Aug, 26-81--9
Jul, 26-81--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 02, 2026Guggenheim$26.00$9.37177.48%185.09%
Sep 28, 2026Brandon FolkesH.C. Wainwright$29.00$9.24213.85%217.98%
Sep 24, 2026Andrea NewkirkGoldman Sachs$7.00$10.42-32.82%-23.25%
Sep 09, 2026Eliana MerleBarclays$18.00$10.7168.07%97.37%
Jan 27, 2026Eliana MerleBarclays$8.00$6.0931.36%-12.28%
Jun 28, 2024Andrea TanGoldman Sachs$6.00$4.1145.99%-34.21%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 22, 2026H.C. WainwrightBuyBuyhold
Oct 02, 2026GuggenheimBuyBuyhold
Oct 01, 2026Cantor FitzgeraldOverweightOverweighthold
Oct 01, 2026CitigroupOutperformOutperformhold
Oct 01, 2026CitigroupMarket OutperformMarket Outperformhold
Sep 28, 2026H.C. WainwrightBuyBuyhold
Sep 09, 2026Cantor FitzgeraldOverweightinitialise
Sep 09, 2026BarclaysOverweightupgrade
Aug 14, 2026CitigroupOutperformOutperformhold
Aug 14, 2026CitigroupMarket OutperformMarket Outperformhold

Financial Forecast

EPS Forecast

$-40 $-32 $-24 $-16 $-8 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.53$-1.45$-1.58---
Avg Forecast$-37.28$-1.49$-3.34$-4.34$-5.83$-3.58
High Forecast$-37.28$-1.42$-2.83$-0.95$-4.37$-3.58
Low Forecast$-37.28$-1.65$-4.10$-6.80$-7.68$-3.58
Surprise %-95.90%-2.68%-52.69%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.00M-----
Avg Forecast$2.00M$2.00M$1.25M$21.00K$29.40M$100.68M
High Forecast$2.00M$2.00M$1.25M$21.00K$29.40M$100.68M
Low Forecast$2.00M$2.00M$1.25M$21.00K$29.40M$100.68M
Surprise %------

Net Income Forecast

$-400M $-320M $-240M $-160M $-80M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-27.88M$-45.57M$-51.04M---
Avg Forecast$-389.91M$-16.05M$-36.21M$-40.53M$-63.03M$-37.41M
High Forecast$-389.91M$-14.89M$-29.55M$-9.97M$-45.69M$-37.41M
Low Forecast$-389.91M$-17.21M$-42.87M$-71.09M$-80.36M$-37.41M
Surprise %-92.85%183.86%40.95%---

SGMT Forecast FAQ

Is Sagimet Biosciences stock a buy?

Sagimet Biosciences stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Sagimet Biosciences is a favorable investment for most analysts.

What is Sagimet Biosciences's price target?

Sagimet Biosciences's price target, set by 9 Wall Street analysts, averages $20 over the next 12 months. The price target range spans from $7 at the low end to $29 at the high end, suggesting a potential 119.30% change from the previous closing price of $9.12.

How does Sagimet Biosciences stock forecast compare to its benchmarks?

Sagimet Biosciences's stock forecast shows a 119.30% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Sagimet Biosciences over the past three months?

  • November 2026: 16.67% Strong Buy, 75.00% Buy, 0% Hold, 8.33% Sell, 0% Strong Sell.
  • October 2026: 16.67% Strong Buy, 75.00% Buy, 0% Hold, 8.33% Sell, 0% Strong Sell.
  • September 2026: 10.00% Strong Buy, 80.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Sagimet Biosciences’s EPS forecast?

Sagimet Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.34, marking a 174.68% increase from the reported $-1.58 in 2025. Estimates for the following years are $-5.83 in 2027, and $-3.58 in 2028.

What is Sagimet Biosciences’s revenue forecast?

Sagimet Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $21K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $29.4M, and $100.68M for 2028.

What is Sagimet Biosciences’s net income forecast?

Sagimet Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-40.53M, representing a -20.59% decrease from the reported $-51.038M in 2025. Projections indicate $-63.025M in 2027, and $-37.413M in 2028.